Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial

BACKGROUND: The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neoadjuvant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Trials
Autors principals: Wu, Wei, Deng, Heran, Rao, Nanyan, You, Na, Yang, Yaping, Cao, Minghui, Liu, Jieqiong
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655944/
https://ncbi.nlm.nih.gov/pubmed/29070044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-017-2228-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars